A Phase 2 Study of Carboplatin, Pemetrexed, and Bevacizumab followed by Bevacizumab and Erlotinib maintenance for Non-squamous Non-Small Cell Lung Cancer not harboring EGFR mutations. (HOT1101) - A Phase 2 Study of Carboplatin, Pemetrexed, and Bevacizumab followed by Bevacizumab and Erlotinib maintenance for Non-squamous Non Small Cell Lung Cancer not harboring EGFR mutations. (HOT1101)

Hokkaido Lung Cancer Clinical Study Group0 个研究点目标入组 51 人开始时间: 2011年6月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•1)Previous histories of drug allergy, which may increase the risk of this study. 2)Serious concomitant infection. 3)Usages of oral steroids or immunosuppressive drugs. 4)Serious complications including severe cardiovascular disease, cerebrovascular disease, severe hypertension, active peptic ulcer, uncontrolled diabetes. 5)Interstitial pneumonia or pulmonary fibrosis on chest CT scans. 6)Patients with EGFR mutation. 7)Severe pleural, abdominal or cardiac effusion. 8)Prior to study entry major surgical procedures within 3 weeks or prior systemic therapy to contain radiotherapy within 2 weeks. 9)Patient in acknowledgment of hemoptysis (2.5 ml or more) or clinically important bleeding or a clot-related event. 10)No uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 90 mmHg). 11)Symptomatic brain metastasis. 12)The patient that the tumor permeation to chest great vessels is accepted. 13)cavity in tumor. 14)receiving anticoagulant drug(except Aspirin under 325mg/day). 15)Patients with active concomitant malignancy. 16)Pregnant, lactating women. 17)Inappropriate patients judged by physicians.

发起方

Hokkaido Lung Cancer Clinical Study Group